$PXMD
PaxMedica, Inc.

2024 Q2 Form 10-Q Financial Statement

#000155837024007980 Filed on May 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.297M
YoY Change -13.55%
% of Gross Profit
Research & Development $1.509M $392.8K
YoY Change 156.27% 76.55%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.999M $3.690M
YoY Change -10.7% -8.58%
Operating Profit -$2.999M -$3.690M
YoY Change -10.7% -8.58%
Interest Expense $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $729.00 -$3.022K
YoY Change -100.57% -101.49%
Pretax Income -$3.693M
YoY Change -3.67%
Income Tax
% Of Pretax Income
Net Earnings -$2.998M -$3.700M
YoY Change -14.01% -3.49%
Net Earnings / Revenue
Basic Earnings Per Share -$0.39 -$0.50
Diluted Earnings Per Share -$0.39 -$0.50
COMMON SHARES
Basic Shares Outstanding 7.780M 7.408M
Diluted Shares Outstanding 7.656M 7.418M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.627M
YoY Change -59.19%
Cash & Equivalents $324.5K $1.627M
Short-Term Investments
Other Short-Term Assets $1.266M
YoY Change 65.26%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $799.6K $2.893M
YoY Change -84.46% -39.12%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $799.6K $2.893M
Total Long-Term Assets $0.00 $0.00
Total Assets $799.6K $2.893M
YoY Change -84.46% -39.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.042M $1.138M
YoY Change 210.02% 136.97%
Accrued Expenses $65.13K
YoY Change -60.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.107M $1.203M
YoY Change -13.11% -33.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $500.0K
YoY Change
Total Long-Term Liabilities $500.0K
YoY Change 18.98%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.107M $1.203M
Total Long-Term Liabilities $500.0K
Total Liabilities $2.607M $1.703M
YoY Change -9.44% -23.27%
SHAREHOLDERS EQUITY
Retained Earnings -$58.70M -$55.70M
YoY Change 42.82% 48.14%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.808M $1.190M
YoY Change
Total Liabilities & Shareholders Equity $799.6K $2.893M
YoY Change -84.46% -39.12%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$2.998M -$3.700M
YoY Change -14.01% -3.49%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.100M
YoY Change 3.33%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -15.28K
YoY Change -100.3%
NET CHANGE
Cash From Operating Activities -3.100M
Cash From Investing Activities
Cash From Financing Activities -15.28K
Net Change In Cash -3.115M
YoY Change -250.66%
FREE CASH FLOW
Cash From Operating Activities -$3.100M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
CY2024Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001811623
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7401242
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7465629
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
0
CY2024Q1 us-gaap Short Term Investments
ShortTermInvestments
0
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
PAXMEDICA, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity File Number
EntityFileNumber
001-41475
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0870387
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
303 South Broadway, Suite 125
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Tarrytown
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10591
CY2024Q1 dei City Area Code
CityAreaCode
914
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
987-2876
CY2024Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
PXMD
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7779860
CY2024Q1 us-gaap Cash
Cash
1626892
CY2023Q4 us-gaap Cash
Cash
4710642
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1266211
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
969763
CY2024Q1 us-gaap Assets Current
AssetsCurrent
2893103
CY2023Q4 us-gaap Assets Current
AssetsCurrent
5680405
CY2024Q1 us-gaap Assets
Assets
2893103
CY2023Q4 us-gaap Assets
Assets
5680405
CY2024Q1 pxmd Accrued Liabilities Excluding Employee Related Liabilities Current
AccruedLiabilitiesExcludingEmployeeRelatedLiabilitiesCurrent
65128
CY2023Q4 pxmd Accrued Liabilities Excluding Employee Related Liabilities Current
AccruedLiabilitiesExcludingEmployeeRelatedLiabilitiesCurrent
177118
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
787981
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1203095
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1795332
CY2024Q1 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
500000
CY2023Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
500000
CY2024Q1 us-gaap Liabilities
Liabilities
1703095
CY2023Q4 us-gaap Liabilities
Liabilities
2295332
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7465629
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7401242
CY2024Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
747
CY2023Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
740
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
56912182
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
55414069
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55722926
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52029741
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
1190008
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3385073
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2893103
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5680405
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3297350
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3814184
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
392813
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
222491
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
3690163
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
4036675
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3690163
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4036675
CY2023Q1 us-gaap Interest Expense
InterestExpense
3928
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-36850
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
335364
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3022
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-91658
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3022
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
202928
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3693185
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3833747
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7418281
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
743373
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7418281
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
743373
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.16
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.16
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3385073
CY2024Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-15279
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1513399
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3693185
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
1190008
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
108800
CY2023Q1 pxmd Stock Issued During Period Value Reclassification Of Shares Settled Liability To Equity
StockIssuedDuringPeriodValueReclassificationOfSharesSettledLiabilityToEquity
126449
CY2023Q1 pxmd Stock Issued During Period Value Equity Purchase Agreement
StockIssuedDuringPeriodValueEquityPurchaseAgreement
2805000
CY2023Q1 pxmd Debt Conversion Converted Instrument Warrants Or Options Issued Value
DebtConversionConvertedInstrumentWarrantsOrOptionsIssuedValue
1155643
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2170622
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3833747
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2532767
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-3693185
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-3833747
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1513399
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2170622
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
335364
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-36850
CY2023Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
91658
CY2024Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
296448
CY2023Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
463741
CY2024Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
326234
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
125037
CY2024Q1 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-18500
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-20000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-899971
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-754660
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3068471
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2983345
CY2023Q1 pxmd Proceeds From Issuance Of Common Stock And Warrants Net Of Fees
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfFees
3200000
CY2023Q1 pxmd Proceeds From Convertible Promissory Notes And Warrants
ProceedsFromConvertiblePromissoryNotesAndWarrants
-503696
CY2023Q1 pxmd Proceeds From Issuance Of Common Stock Equity Purchase Agreement
ProceedsFromIssuanceOfCommonStockEquityPurchaseAgreement
2805000
CY2023Q1 pxmd Payments Of Costs Incurred In Connection With Equity Purchase Agreement
PaymentsOfCostsIncurredInConnectionWithEquityPurchaseAgreement
195997
CY2024Q1 pxmd Prepaid Legal And Professional Services
PrepaidLegalAndProfessionalServices
400000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
800000
CY2023Q1 pxmd Accrued Costs For Research And Development Activities
AccruedCostsForResearchAndDevelopmentActivities
600000
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
200000
CY2023Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
237600
CY2024Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
15279
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-15279
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5067707
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3083750
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2084362
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4710642
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1901887
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1626892
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3986249
CY2023Q1 pxmd Reclassification Of Shares Settled Liability
ReclassificationOfSharesSettledLiability
126449
CY2023Q1 pxmd Unpaid Offering Costs
UnpaidOfferingCosts
20393
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 1. Organization and description of business operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">PaxMedica, Inc. (the “Company”) is a clinical stage biopharmaceutical company organized as a Delaware limited liability company on April 5, 2018 (“Inception”) to focus on the development of drug candidates for the treatment of autism spectrum disorder (ASD), Fragile X syndrome tremor-ataxia (FXTAS) and Human African Trypanosomiasis (HAT).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Going concern, liquidity and capital resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has no product revenues, incurred operating losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The Company had an accumulated deficit of approximately $55.7 million at March 31, 2024, a net loss of approximately $3.7 million, and approximately $3.1 million of net cash used in operating activities for the three months ended March 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Equity Purchase Agreement with Lincoln Park Capital</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 17, 2022, the Company entered into an equity purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“LPC”) which provided that, upon the terms and subject to the conditions and limitations set forth therein, the Company could sell to LPC, at its discretion, up to $20.0 million of shares of its common stock over the 30-month term of the Purchase Agreement (See Note 7). During the three months ended March 31, 2024 there were no shares of common stock issued in connection with the Purchase Agreement. During the three months ended March 31, 2023, the Company received approximately $2.6 million from the issuance of 70,592 shares of common stock, net of fees of $0.2 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-color:#000000;text-decoration-line:none;">Convertible Promissory Note</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company issued the 2023 Note in February 2023 with a principal balance of $3.7 million. In connection with the issuance, the Company received proceeds of approximately $3.2 million, net of a $0.5 million discount, incurred fees of approximately $0.5 million and used $0.2 million of proceeds pay down the remaining balance of the Company’s 2022 Notes. In connection with the 2023 Note, the Company issued a common stock warrant to purchase 47,059 shares of the Company’s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 29, 2023, the Company satisfied in full the obligations under its outstanding secured convertible promissory note with Lind Global Fund II LP, through a final cash payment of $0.2 million. The satisfaction of the remaining open payment obligations under the Note terminates the Note in full and retires all of the Company's payment obligations thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Vox Nova Exclusive Pharmacy Distribution Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On June 30, 2023, the Company entered into an exclusive specialty benefit manager agreement with Vox Nova, LLC (“Vox Nova”) pursuant to which Vox Nova will act as the exclusive United States distributor for the Company’s lead pipeline asset, PAX-101 intravenous suramin. Vox Nova will provide certain distribution management, pharmacy benefit management, sales and supply monitoring services to the Company with respect to PAX-101, in the event PAX-101 receives FDA approval. The distribution agreement also provides for an exclusivity fee payable to the Company of up to $2.0 million, payable in installments based on various time and regulatory approval parameters. Vox Nova will pay $0.5 million of the exclusivity fee upfront in connection with the signing of the distribution agreement when the distribution right was transferred to Vox Nova. The remaining $1.5 million is due in four equal installments over a one-year period after PAX-101 is approved by the FDA and made available for distribution. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Reverse Stock Split</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 30, 2023, we filed a Certificate of Amendment to our Certificate of Incorporation (the “Reverse Split Amendment”) with the Secretary of State of the State of Delaware to effect a <span style="-sec-ix-hidden:Hidden_hx29Boj_mE6eyOangTGsHg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1-for-17</span></span> reverse stock split of our outstanding common stock (the “Reverse Stock Split”). The Amendment became effective October 30, 2023 (the “Reverse Split Effective Time”). The Reverse Split Amendment was authorized by our stockholders at our special meeting of stockholders on September 26, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Reverse Split Amendment provides that, at the Reverse Split Effective Time, every <span style="-sec-ix-hidden:Hidden_NBMIIM4EKkmWgj8dSpGOBg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">17</span></span> shares of our issued and outstanding common stock were automatically combined into one issued and outstanding share of common stock, without any change in par value per share. The Reverse Stock Split affected all or our shares of common stock outstanding immediately prior to the Reverse Split Effective Time. As a result of the Reserve Stock Split, proportionate adjustments have been made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options and warrants issued and outstanding immediately prior to the Reverse Split Effective Time, which resulted in a proportionate decrease in the number of shares of our common stock reserved for issuance upon exercise or vesting of such stock options and warrants, and, in the case of stock options and warrants, a proportionate increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under our 2020 Plan (as defined below) immediately prior to the Reverse Split Effective Time has been reduced proportionately.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">No fractional shares were issued as a result of the Reverse Stock Split. Stockholders of record who would otherwise have been entitled to receive a fractional share received a number of shares rounded up to the next whole share in lieu thereof. The Reverse Stock Split affected all stockholders proportionately and did not affect any stockholder’s percentage ownership of our common stock (other than the nominal effect of the treatment of fractional shares).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our common stock began trading on The Nasdaq Capital Market on a split-adjusted basis when the market opened on October 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All share and per share information referenced throughout this Form 10-Q has been retroactively adjusted to reflect the Reverse Stock Split. Any fractional shares resulting from the Reverse Stock Split have been rounded up to the nearest whole share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Delisting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company’s common stock was suspended from trading on the Nasdaq Capital Market on May 2, 2024.  Beginning May 2, 2024, the Company’s common stock had been trading over the counter on the OTC Markets’ Pink Sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-color:#000000;text-decoration-line:none;">Going Concern</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying condensed financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s future liquidity and capital funding requirements will depend on numerous factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its ability to raise additional funds to finance its operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcome, costs and timing of clinical trial results for the Company’s current or future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the emergence and effect of competing or complementary products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its ability to maintain, expand and defend the scope of its intellectual property portfolio, including the amount and timing of any payments the Company may be required to make, or that it may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its ability to retain its current employees and the need and ability to hire additional management and scientific and medical personnel; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of any collaborative, licensing or other arrangements that it has or may establish.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company will likely need to raise substantial additional funds through one or more of the following: issuance of additional debt or equity, or the completion of a licensing transaction for one or more of the Company’s pipeline assets. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future clinical studies and/or other future ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on the Company’s business operations. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or convertible debt financings will likely have a dilutive effect on the holdings of the Company’s existing stockholders. Accordingly, there are material risks and uncertainties that raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the issuance of these condensed financial statements. The accompanying condensed financial statements do not include any adjustments that result from the outcome of these uncertainties.</p>
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55700000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3700000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3100000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed financial statements relate to the valuation of convertible notes, valuation of warrants, and valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p>
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2024Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6048380
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
331491
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
173543
CY2023Q1 pxmd Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issuances Of Convertible Notes
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuancesOfConvertibleNotes
1903531
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
237600
CY2023Q1 pxmd Fair Value Liabilities Measured On Recurring Basis Unobservable Inputs Reconciliation Loss On Extinguishment Of Debt
FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputsReconciliationLossOnExtinguishmentOfDebt
-36850
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
335364
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1540960
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1300000
CY2024Q1 pxmd Accrued Costs For Research And Development Activities
AccruedCostsForResearchAndDevelopmentActivities
900000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1513399
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2170622
CY2023Q1 us-gaap Litigation Reserve
LitigationReserve
0
CY2024Q1 us-gaap Litigation Reserve
LitigationReserve
0

Files In Submission

Name View Source Status
0001558370-24-007980-index-headers.html Edgar Link pending
0001558370-24-007980-index.html Edgar Link pending
0001558370-24-007980.txt Edgar Link pending
0001558370-24-007980-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pxmd-20240331.xsd Edgar Link pending
pxmd-20240331x10q.htm Edgar Link pending
pxmd-20240331x10q_htm.xml Edgar Link completed
pxmd-20240331xex31d1.htm Edgar Link pending
pxmd-20240331xex31d2.htm Edgar Link pending
pxmd-20240331xex32d1.htm Edgar Link pending
pxmd-20240331xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
pxmd-20240331_cal.xml Edgar Link unprocessable
pxmd-20240331_lab.xml Edgar Link unprocessable
pxmd-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
pxmd-20240331_def.xml Edgar Link unprocessable